Cargando…

High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus

INTRODUCTION: High Mobility Group Box 1 (HMGB1) is a nuclear non-histone protein. HMGB1, which is secreted by inflammatory cells and passively released from apoptotic and necrotic cells, may act as a pro-inflammatory mediator. As apoptotic cells accumulate in systemic lupus erythematosus (SLE), HMGB...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdulahad, Deena A, Westra, Johanna, Bijzet, Johannes, Limburg, Pieter C, Kallenberg, Cees GM, Bijl, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218880/
https://www.ncbi.nlm.nih.gov/pubmed/21548924
http://dx.doi.org/10.1186/ar3332
_version_ 1782216748641026048
author Abdulahad, Deena A
Westra, Johanna
Bijzet, Johannes
Limburg, Pieter C
Kallenberg, Cees GM
Bijl, Marc
author_facet Abdulahad, Deena A
Westra, Johanna
Bijzet, Johannes
Limburg, Pieter C
Kallenberg, Cees GM
Bijl, Marc
author_sort Abdulahad, Deena A
collection PubMed
description INTRODUCTION: High Mobility Group Box 1 (HMGB1) is a nuclear non-histone protein. HMGB1, which is secreted by inflammatory cells and passively released from apoptotic and necrotic cells, may act as a pro-inflammatory mediator. As apoptotic cells accumulate in systemic lupus erythematosus (SLE), HMGB1 levels might be increased in SLE. HMGB1 may also serve as an autoantigen, leading to the production of anti-HMGB1 antibodies. In this study we determined levels of HMGB1 and anti-HMGB1 in SLE patients in comparison to healthy controls (HC) and analysed their relation with disease activity. METHODS: The study population consisted of 70 SLE patients and 35 age- and sex-matched HC. Thirty-three SLE patients had quiescent disease, the other 37 patients were selected for having active disease. Nineteen of these had lupus nephritis. HMGB1 levels were measured with both Western blot and ELISA. Anti-HMGB1 levels were measured by ELISA. Clinical and serological parameters were assessed according to routine procedures. RESULTS: HMGB1 levels in SLE patients could be measured reliably by Western blotting only, and were significantly increased compared to HC. During active disease HMGB1 levels increased, in particular in patients with renal involvement. Serum HMGB1 levels correlated with SLEDAI, proteinuria, and anti-dsDNA levels, and showed a negative correlation with complement C3. Anti-HMGB1 levels were significantly increased in SLE patients compared to HC, and positively correlated with HMGB1 levels. CONCLUSIONS: Levels of HMGB1 in the sera of SLE patients, in particular in those with active renal disease, are increased. Serum HMGB1 levels are related to SLEDAI scores and proteinuria, as well as to levels of anti-HMGB1 antibodies. These findings suggest that besides HMGB1, HMGB1-anti-HMGB1 immune complexes play a role in the pathogenesis of SLE, in particular in patients with renal involvement.
format Online
Article
Text
id pubmed-3218880
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32188802011-11-18 High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus Abdulahad, Deena A Westra, Johanna Bijzet, Johannes Limburg, Pieter C Kallenberg, Cees GM Bijl, Marc Arthritis Res Ther Research Article INTRODUCTION: High Mobility Group Box 1 (HMGB1) is a nuclear non-histone protein. HMGB1, which is secreted by inflammatory cells and passively released from apoptotic and necrotic cells, may act as a pro-inflammatory mediator. As apoptotic cells accumulate in systemic lupus erythematosus (SLE), HMGB1 levels might be increased in SLE. HMGB1 may also serve as an autoantigen, leading to the production of anti-HMGB1 antibodies. In this study we determined levels of HMGB1 and anti-HMGB1 in SLE patients in comparison to healthy controls (HC) and analysed their relation with disease activity. METHODS: The study population consisted of 70 SLE patients and 35 age- and sex-matched HC. Thirty-three SLE patients had quiescent disease, the other 37 patients were selected for having active disease. Nineteen of these had lupus nephritis. HMGB1 levels were measured with both Western blot and ELISA. Anti-HMGB1 levels were measured by ELISA. Clinical and serological parameters were assessed according to routine procedures. RESULTS: HMGB1 levels in SLE patients could be measured reliably by Western blotting only, and were significantly increased compared to HC. During active disease HMGB1 levels increased, in particular in patients with renal involvement. Serum HMGB1 levels correlated with SLEDAI, proteinuria, and anti-dsDNA levels, and showed a negative correlation with complement C3. Anti-HMGB1 levels were significantly increased in SLE patients compared to HC, and positively correlated with HMGB1 levels. CONCLUSIONS: Levels of HMGB1 in the sera of SLE patients, in particular in those with active renal disease, are increased. Serum HMGB1 levels are related to SLEDAI scores and proteinuria, as well as to levels of anti-HMGB1 antibodies. These findings suggest that besides HMGB1, HMGB1-anti-HMGB1 immune complexes play a role in the pathogenesis of SLE, in particular in patients with renal involvement. BioMed Central 2011 2011-05-06 /pmc/articles/PMC3218880/ /pubmed/21548924 http://dx.doi.org/10.1186/ar3332 Text en Copyright ©2011 Abdulahad et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Abdulahad, Deena A
Westra, Johanna
Bijzet, Johannes
Limburg, Pieter C
Kallenberg, Cees GM
Bijl, Marc
High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus
title High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus
title_full High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus
title_fullStr High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus
title_full_unstemmed High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus
title_short High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus
title_sort high mobility group box 1 (hmgb1) and anti-hmgb1 antibodies and their relation to disease characteristics in systemic lupus erythematosus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218880/
https://www.ncbi.nlm.nih.gov/pubmed/21548924
http://dx.doi.org/10.1186/ar3332
work_keys_str_mv AT abdulahaddeenaa highmobilitygroupbox1hmgb1andantihmgb1antibodiesandtheirrelationtodiseasecharacteristicsinsystemiclupuserythematosus
AT westrajohanna highmobilitygroupbox1hmgb1andantihmgb1antibodiesandtheirrelationtodiseasecharacteristicsinsystemiclupuserythematosus
AT bijzetjohannes highmobilitygroupbox1hmgb1andantihmgb1antibodiesandtheirrelationtodiseasecharacteristicsinsystemiclupuserythematosus
AT limburgpieterc highmobilitygroupbox1hmgb1andantihmgb1antibodiesandtheirrelationtodiseasecharacteristicsinsystemiclupuserythematosus
AT kallenbergceesgm highmobilitygroupbox1hmgb1andantihmgb1antibodiesandtheirrelationtodiseasecharacteristicsinsystemiclupuserythematosus
AT bijlmarc highmobilitygroupbox1hmgb1andantihmgb1antibodiesandtheirrelationtodiseasecharacteristicsinsystemiclupuserythematosus